HC Wainwright Comments on Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Krystal Biotech in a report issued on Wednesday, February 19th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of $1.56 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.74 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.24 EPS, FY2025 earnings at $6.97 EPS, FY2026 earnings at $6.23 EPS, FY2027 earnings at $8.49 EPS and FY2028 earnings at $8.78 EPS.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS.

KRYS has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup raised their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $186.89 on Monday. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 62.51 and a beta of 0.84. The stock has a 50 day moving average price of $157.85 and a 200-day moving average price of $175.26. Krystal Biotech has a one year low of $125.85 and a one year high of $219.34.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. raised its position in Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. State Street Corp raised its position in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).